Adebrelimab combinations for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a type of immunotherapy called adebrelimab (a medicine that helps your immune system attack cancer) either alone or with other treatments in people with advanced solid tumors, including small cell lung cancer. The goal is to see if this approach can help control the cancer or improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a type of cancer that has spread or come back after treatment, such as small cell lung cancer or another solid tumor (not blood cancer).
- Your doctor must think you might benefit from a medicine called adebrelimab, which helps your immune system fight cancer.
- If you have small cell lung cancer that got worse after first-line treatment, you may be able to join a second part of the study.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use birth control during the study and for 90 days after the last dose.
- You must be able to follow the study plan and come for follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HS-20093) alone versus combined with another drug (adebrelimab) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already been treated. The goal is to see if the combination works better at shrinking tumors or slowing cancer growth.
This study tests a new combination of two drugs for small cell lung cancer that has grown after the first round of treatment. The goal is to see if the combination can slow or stop the cancer and to look for markers that predict who benefits.
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.